Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $8.98 and last traded at $9.09, with a volume of 138021 shares. The stock had previously closed at $9.59.
Analyst Ratings Changes
A number of brokerages have recently weighed in on NMRA. Royal Bank of Canada restated an "outperform" rating and issued a $31.00 target price on shares of Neumora Therapeutics in a research note on Thursday, March 28th. William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. Finally, JPMorgan Chase & Co. boosted their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an "overweight" rating in a research note on Monday, March 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $22.57.
Check Out Our Latest Stock Report on Neumora Therapeutics
Neumora Therapeutics Stock Down 5.5 %
The firm has a 50 day moving average of $14.86 and a 200 day moving average of $14.08.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.05. As a group, equities analysts expect that Neumora Therapeutics, Inc. will post -1.48 EPS for the current year.
Institutional Investors Weigh In On Neumora Therapeutics
Several institutional investors have recently made changes to their positions in NMRA. Addis & Hill Inc bought a new position in shares of Neumora Therapeutics in the first quarter worth $4,187,000. Windmill Hill Asset Management Ltd bought a new position in shares of Neumora Therapeutics in the first quarter worth $359,000. Avidity Partners Management LP increased its holdings in shares of Neumora Therapeutics by 10.6% in the fourth quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company's stock worth $33,940,000 after purchasing an additional 190,632 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Neumora Therapeutics in the fourth quarter worth $44,000. Finally, Amalgamated Bank bought a new position in shares of Neumora Therapeutics in the fourth quarter worth $29,000. Hedge funds and other institutional investors own 47.65% of the company's stock.
Neumora Therapeutics Company Profile
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
